ERBB2 and breast carcinoma: In recent years, human epidermal growth factor receptor 2 (HER2)-positive breast cancer and TNBC have been increasingly indicated for preoperative chemotherapy with the introduction of the residual disease-guided approach and immune checkpoint inhibitors [18, 19].